SAN FRANCISCO, Jan. 22, 2024 /PRNewswire/ -- Invitae (NVTA) (NYSE: NVTA), a leading medical genetics company, today announced it has completed the sale of certain reproductive health assets, which ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has acquired from Invitae (NYSE: NVTA), a leading medical ...

Invitae Corp. continued its aggressive cost-cutting initiative with the sale of its reproductive health assets to Natera Inc. for $10 million in upfront cash and an additional $42.5 million in ...

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...

DUBLIN--(BUSINESS WIRE)--The "Global Non-Invasive Prenatal Testing Market Report by Application Component End User Countries and Company Analysis, 2024-2032" report has been added to ...

The wide ranging Prenatal Genetic Testing business report displays a professional and all-inclusive study of the Prenatal Genetic Testing industry which focuses on primary and secondary drivers, ...

Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin ...

Seeing the plus sign on a pregnancy test can be one of the most emotional moments of your life. You might feel ecstatic, scared, relieved, hopeful, nervous, or all of the above (let’s be honest, it’s ...